Evidence map›Paper›PMID 32587329›Full record

ArticleScientific reports2020

Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.

Takahisa Yamashita, Morihiro Higashi, Shuji Momose, Akiko Adachi, Toshiki Watanabe, Yuka Tanaka, Michihide Tokuhira, Masahiro Kizaki, Jun-Ichi Tamaru

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Takahisa YamashitaDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Morihiro HigashiDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Shuji MomoseDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Akiko AdachiDepartment of Pathology, Saitama Red Cross Hospital, Saitama, Japan.
Toshiki WatanabeMedical Genome Sciences, Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yuka TanakaDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Michihide TokuhiraDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Masahiro KizakiDepartment of Hematology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
Jun-Ichi TamaruDepartment of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. jtamaru@saitama-med.ac.jp.
Saitama Medical University · JPSocial Insurance Saitama Chuo Hospital · JPSaitama Red Cross Hospital · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MYC-associated factor X (MAX) is a protein in the basic helix-loop-helix leucine zipper family, which is ubiquitously and constitutively expressed in various normal tissues and tumors. MAX protein mediates various cellular functions such as proliferation, differentiation, and apoptosis through the MYC-MAX protein complex. Recently, it has been reported that MYC regulates the proliferation of anaplastic large cell lymphoma. However, the expression and function of MAX in anaplastic large cell lymphoma remain to be elucidated. We herein investigated MAX expression in anaplastic large cell lymphoma (ALCL) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and found 11 of 37 patients (30%) with ALCL lacked MAX expression, whereas 15 of 15 patients (100%) with PTCL-NOS expressed MAX protein. ALCL patients lacking MAX expression had a significantly inferior prognosis compared with patients having MAX expression. Moreover, patients without MAX expression significantly had histological non-common variants, which were mainly detected in aggressive ALCL cases. Immunohistochemical analysis showed that MAX expression was related to the expression of MYC and cytotoxic molecules. These findings demonstrate that lack of MAX expression is a potential poor prognostic biomarker in ALCL and a candidate marker for differential diagnosis of ALCL and PTCL-NOS.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorFemaleFollow-Up StudiesHumansLymphoma, Large-Cell, AnaplasticLymphoma, T-Cell, PeripheralMaleMiddle AgedPrognosisSurvival RateBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorMAX protein, human

Identifiers

PMID32587329
PMCPMC7316730
OpenAlexW3037911332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.